Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iain Simpson

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Bioorganic & Medicinal Chemistry Letters|June 3, 2023
Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitorsNeil P Grimster, Lakshmaiah Gingipalli, Amber Balazs, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2020
Optimization of a series of potent, selective and orally bioavailable SYK inhibitorsNeil P Grimster, Lakshmaiah Gingipalli, Bernard Barlaam, et al.
Journal of Medicinal Chemistry|November 12, 2019
Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)Richard A Ward, Mark J Anderton, Paul Bethel, et al.
Journal of Medicinal Chemistry|July 3, 2023
Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRAS<sup>G12C</sup> with Demonstrable CNS PenetrationJason G Kettle, Sharan K Bagal, Derek Barratt, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Bioorganic & Medicinal Chemistry Letters|June 3, 2023
Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitorsNeil P Grimster, Lakshmaiah Gingipalli, Amber Balazs, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2020
Optimization of a series of potent, selective and orally bioavailable SYK inhibitorsNeil P Grimster, Lakshmaiah Gingipalli, Bernard Barlaam, et al.
Journal of Medicinal Chemistry|November 12, 2019
Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)Richard A Ward, Mark J Anderton, Paul Bethel, et al.
Journal of Medicinal Chemistry|July 3, 2023
Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRAS<sup>G12C</sup> with Demonstrable CNS PenetrationJason G Kettle, Sharan K Bagal, Derek Barratt, et al.
Pageof 5